<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Neurology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F06C682B-506E-4EE0-BED1-7577333B8D21"><gtr:id>F06C682B-506E-4EE0-BED1-7577333B8D21</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Devine</gtr:surname><gtr:orcidId>0000-0001-6076-3382</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800437"><gtr:id>088F77A4-8009-49BF-9E45-1020D33DE887</gtr:id><gtr:title>Development of a novel cell model for LRRK2 Parkinson's Disease</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0800437</gtr:grantReference><gtr:abstractText>Parkinson?s disease (PD) is a very common and devastating neurological condition which leads to progressive difficulty with movement and memory. The disease is caused by certain nerve cells gradually dying in the brain. However, little is known about why this happens and currently there is no cure.

Rarely, certain genetic mutations can lead to PD being inherited in families. Understanding how these mutations cause disease in these families can help us to understand the more common form of PD in the general population.

We are investigating the most common form of inherited PD which occurs due to mutations in a gene called LRRK2. Our aim is to develop a novel model for PD using skin cells from PD patients who have these particular mutations. Using new techniques, we can convert these cells into the specific nerve cells that die in PD. By comparing these cells to equivalent cells from healthy individuals, we plan to find out precisely how LRRK2 mutations cause disease.

Our understanding of how LRRK2 causes PD will be harnessed to develop strategies to intervene in this process. This will ultimately enable us to develop treatments that halt the development and advancement of the common form of PD.</gtr:abstractText><gtr:technicalSummary>Parkinson?s disease (PD) is the most common neurodegenerative movement disorder. The pathology of progressive loss of dopaminergic neurons in the substantia nigra is well known, but the mechanisms by which this occurs are not understood. As a consequence, curative treatments for this disease currently do not exist.

Progress in our understanding of the pathological changes has been made by studying the rare inherited forms of the disease: these individual mutations can provide a foothold for understanding the pathogenesis of PD. However, it is not clear whether these inherited cases represent the same condition as sporadic PD.

We are investigating the most common form of inherited PD, caused by mutations in LRRK2 - which replicates the phenotype of sporadic PD very closely. Previous work has suggested that the kinase domain of LRRK2 plays a pivotal role, with some of its mutations being associated with increased kinase activity, whilst the toxicity of mutated LRRK2 is reduced when it is expressed on a kinase dead background. However, it is unclear whether this is the case with all disease-causing LRRK2 mutations, and progress is hampered because studies rely upon cell models derived from tumour cells or rodent neurons, which are very different to the cells that degenerate in PD. New model systems are required in order to take matters forward.
 
Our aim is to develop a novel cell model of LRRK2 PD using fibroblasts from PD patients with LRRK2 mutations, taken from skin tissue obtained by punch biopsy. Using new techniques, pioneered by Takahashi and Yamanaka at the University of Kyoto, these cells will be stimulated to enter a stem-cell-like state, after which they will be induced to form dopaminergic neurons, mimicking the cells that degenerate in PD.

Cells carrying LRRK2 mutations will be compared with equivalent cells from control subjects at both the fibroblast and dopaminergic neuron level in order to better understand how these mutations lead to neunal death. Kinase behaviour and signal pathway activation will be areas of particular interest. We hope to harness this information to develop strategies to intervene in the pathogenetic pathway in order to develop treatments that could halt neurodegeneration in LRRK2 PD, and therefore ultimately treat the more common sporadic form of the disease.</gtr:technicalSummary><gtr:fund><gtr:end>2012-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>266894</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lund University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:department>Neuronal Survival Unit</gtr:department><gtr:description>Seeding in alpha-synuclein triplication iPSC-derived neurons</gtr:description><gtr:id>35F3028A-36D1-40E0-90E7-5A49055B10B0</gtr:id><gtr:impact>No outcomes as yet.</gtr:impact><gtr:outcomeId>pGj1GcyYB4s-1</gtr:outcomeId><gtr:piContribution>We are working with a group at Lund University on seeding of alpha-synuclein using the iPSC model of Parkinson's disease that we have developed.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Stem Cell Research Edinburgh</gtr:department><gtr:description>Development of an iPSC model of Parkinson's Disease</gtr:description><gtr:id>C80B9CC9-E0C1-4586-B2F5-6C7F6E9B4BE5</gtr:id><gtr:impact>Publication:
Devine MJ, Ryten M, Vodicka P, Thomson AJ, Burdon T, Houlden H, et al. Parkinson's disease induced pluripotent stem cells with triplication of the a-synuclein locus. Nature Communications. 2011;2:440.</gtr:impact><gtr:outcomeId>kmicREQqRpD-1</gtr:outcomeId><gtr:partnerContribution>Training, access to facilities.</gtr:partnerContribution><gtr:piContribution>As part of my MRC clinical research training fellowship, I spent 12 months in Tilo Kunath's lab at the Institute of Stem Cell Research (now part of the MRC Centre for Regenerative Medicine). We successfully developed an iPSC model of Parkinson's Disease, deriving iPSCs and midbrain dopaminergic neurons from a patient with an aggressive, early onset form of Parkinson's disease caused by triplication of the alpha-synuclein locus. We are continuing to work on this model to study the disease process.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Parkinson's UK (Edinburgh branch)</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>87ABB4C4-4809-422D-A4F4-2DCBFA75E34B</gtr:id><gtr:impact>A group of around 20 patients with Parkinson's disease and carers visited Tilo's lab. We gave them a tour of the lab areas, and gave a short presentation of the iPSC project, progress so far and what we plan to do.

Our project could not be carried out without patient involvement - we generate iPSCs from fibroblasts biopsied from patients. Showing patients and carers what we are doing is an important component of their continuing involvement with the work.</gtr:impact><gtr:outcomeId>pgy775Cb6ZJ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Southend Bowls Club</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>C4B497C3-B8F4-48ED-8453-9F6E1A361F6F</gtr:id><gtr:impact>Southend Bowls Club have nominated the National Brain Appeal as their charity for this calender year. They are particularly interested in stem cell research for Parkinson's Disease. As part of that specific interest, John Hardy and myself have visited the club to give short talks on the work we are doing and how their contributions to the National Brain Appeal can help.

Fundraising via the bowls club.</gtr:impact><gtr:outcomeId>fBniWpub2nV</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nature Communications paper press release</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>F5FAC525-8084-4A1E-B549-AF450CE2D8DF</gtr:id><gtr:impact>The publication of the Parkinson's iPSC model in Nature Communications was accompanied by a press release that was picked up by the BBC, the Times (Scotland) and a number of other media outlets.

This was quite recent, but I think it has made more people aware of the project, and stimulated interest.</gtr:impact><gtr:outcomeId>hpQYkxh3C3y</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>430000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Wellcome Trust Research Training Fellowship</gtr:department><gtr:description>Wellcome Postdoctoral Fellowship for Clinicians</gtr:description><gtr:end>2019-01-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>A4DA7AEC-67C2-4446-9149-3ABFA11ADE45</gtr:id><gtr:outcomeId>5510906b810f14.99248251</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>iPSC lines (multiple clones) generated from fibroblasts biopsied from a Parkinson's patient with triplication of the alpha-synuclein locus, and multiple iPSC clones from her unaffected daughter.</gtr:description><gtr:id>C878786A-A09B-4608-8D93-35A83E7BB266</gtr:id><gtr:impact>This resource has only recently been generated and been available to other research groups.</gtr:impact><gtr:outcomeId>UMpZLPUgST7</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Alpha-synuclein triplication iPSC lines and control iPSC lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>133C33C6-8E25-4A05-8885-AEA65669A062</gtr:id><gtr:title>Proteasomal inhibition as a treatment strategy for Parkinson's disease: the impact of a-synuclein on Nurr1.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81b016b620411b3da51cfd468ebe3c2a"><gtr:id>81b016b620411b3da51cfd468ebe3c2a</gtr:id><gtr:otherNames>Devine MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>pm_16611_21_23152591</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4707D535-FF3E-457B-9BD5-5A9733209ACC</gtr:id><gtr:title>A cell culture model for monitoring a-synuclein cell-to-cell transfer.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b59ebbdf07b295714adcff7ae6aad094"><gtr:id>b59ebbdf07b295714adcff7ae6aad094</gtr:id><gtr:otherNames>Reyes JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>54649156208425.37646817</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA18B6EE-C38E-4AA6-9976-3AE02D58DB9C</gtr:id><gtr:title>Pathogenic LRRK2 mutations do not alter gene expression in cell model systems or human brain tissue.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81b016b620411b3da51cfd468ebe3c2a"><gtr:id>81b016b620411b3da51cfd468ebe3c2a</gtr:id><gtr:otherNames>Devine MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pL1zPW2dYqh</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DA58B7C-026A-45DE-9429-1F6E2EA0347A</gtr:id><gtr:title>Parkinson's disease induced pluripotent stem cells with triplication of the a-synuclein locus.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81b016b620411b3da51cfd468ebe3c2a"><gtr:id>81b016b620411b3da51cfd468ebe3c2a</gtr:id><gtr:otherNames>Devine MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>F8zWUMB2Yt5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B1DEBE9-57CE-448A-B075-54C0FD0E4D86</gtr:id><gtr:title>Alpha-Synuclein Oligomers Interact with Metal Ions to Induce Oxidative Stress and Neuronal Death in Parkinson's Disease.</gtr:title><gtr:parentPublicationTitle>Antioxidants &amp; redox signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/948b5c491080c769d4906f5e34a78056"><gtr:id>948b5c491080c769d4906f5e34a78056</gtr:id><gtr:otherNames>Deas E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1523-0864</gtr:issn><gtr:outcomeId>56dd95efdd0853.07382080</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B809C929-00CD-45BA-B429-7C978B0CF0D8</gtr:id><gtr:title>Pathogenic Parkinson's disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation.</gtr:title><gtr:parentPublicationTitle>Biochemical and biophysical research communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3986e9193670c92aaeae6a29e24b678e"><gtr:id>3986e9193670c92aaeae6a29e24b678e</gtr:id><gtr:otherNames>Manzoni C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-291X</gtr:issn><gtr:outcomeId>pm_16611_21_24211199</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA50B1BB-8DA9-4E4B-8E14-EE5BCD5E8A09</gtr:id><gtr:title>Parkinson's disease and cancer: two wars, one front.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81b016b620411b3da51cfd468ebe3c2a"><gtr:id>81b016b620411b3da51cfd468ebe3c2a</gtr:id><gtr:otherNames>Devine MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1474-175X</gtr:issn><gtr:outcomeId>KH84VHFzibc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2547A22E-7FAC-4D3E-95BC-62859C4C1A0B</gtr:id><gtr:title>Creation of an open-access, mutation-defined fibroblast resource for neurological disease research.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68ca09ebb1473b9780612d7b5d9dafef"><gtr:id>68ca09ebb1473b9780612d7b5d9dafef</gtr:id><gtr:otherNames>Wray S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16611_21_22952635</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B3EB809-FF78-4B5D-BC9B-FC4D38A44D09</gtr:id><gtr:title>Emerging pathways in genetic Parkinson's disease: tangles, Lewy bodies and LRRK2.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81b016b620411b3da51cfd468ebe3c2a"><gtr:id>81b016b620411b3da51cfd468ebe3c2a</gtr:id><gtr:otherNames>Devine MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>SdE7gpMDuqZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BBCDFE9-DF40-4C51-8B5C-C813DDFA342F</gtr:id><gtr:title>Rapamycin regulates autophagy and cell adhesion in induced pluripotent stem cells.</gtr:title><gtr:parentPublicationTitle>Stem cell research &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e372bbdf51d4c1ceb956e38877fd3d5"><gtr:id>1e372bbdf51d4c1ceb956e38877fd3d5</gtr:id><gtr:otherNames>Sotthibundhu A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1757-6512</gtr:issn><gtr:outcomeId>58c1468de46ea6.51231534</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2ED9C62A-93EA-4644-B18F-FE5F364628F7</gtr:id><gtr:title>Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10 + 16 splice-site mutation in MAPT.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b39d653d4d3c3376c5d341f10c040edc"><gtr:id>b39d653d4d3c3376c5d341f10c040edc</gtr:id><gtr:otherNames>Sposito T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>56dd95ef9faae3.95404460</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B071ABA3-8237-434F-8E4C-3F0B9D88487C</gtr:id><gtr:title>Generation of human pluripotent stem cell reporter lines for the isolation of and reporting on astrocytes generated from ventral midbrain and ventral spinal cord neural progenitors.</gtr:title><gtr:parentPublicationTitle>Stem cell research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c61dc6e0c7616a3d9aeb16642cf9880a"><gtr:id>c61dc6e0c7616a3d9aeb16642cf9880a</gtr:id><gtr:otherNames>Holmqvist S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1873-5061</gtr:issn><gtr:outcomeId>56dd95ef7da748.09752661</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFF1B4CA-8411-4053-90D8-9BD01ED59D19</gtr:id><gtr:title>Parkinson's disease and a-synuclein expression.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/81b016b620411b3da51cfd468ebe3c2a"><gtr:id>81b016b620411b3da51cfd468ebe3c2a</gtr:id><gtr:otherNames>Devine MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>Vey5mwkbBCy</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7BB88DF4-0261-461E-BD35-CEAC0479B9C7</gtr:id><gtr:title>Clinical features, with video documentation, of the original familial lewy body parkinsonism caused by a-synuclein triplication (Iowa kindred).</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c08488767bed9cf7a157d98487dc252a"><gtr:id>c08488767bed9cf7a157d98487dc252a</gtr:id><gtr:otherNames>Gwinn K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>YKn849NdtdN</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800437</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>